2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Monday, November 11, 2019

2:30PM-4:00PM: Abstract Number: 1847

A National Needs Assessment of Males with SLE: Assessing Medical, Psychosocial, Support & Coping Needs

4M127: Pain, Anxiety, & Depression (1842–1847)

2:30PM-4:00PM: Abstract Number: 1809

A Quarter of Patients Treated with Checkpoint Inhibitors Develop Immune-Related Adverse Events: A University Center Experience

4M091: Miscellaneous Rheumatic & Inflammatory Disease II: Checkpoint Inhibitors-Induced & Other Rheumatic Conditions (1806–1811)

2:30PM-4:00PM: Abstract Number: 1829

Ability of Inflammatory and Regulatory Soluble Mediators to Forecast Impending Clinical Disease Flare and Inform a Refined Lupus Flare Prediction Index in a Confirmatory Cohort of SLE Patients

3S082: SLE – Clinical II: Flares & Morbidity of SLE (1824–1829)

2:30PM-4:00PM: Abstract Number: 1794

An Evaluation of Burnout Among U.S. Rheumatology Fellows: A National Survey

4M089: Education (1794–1799)

2:30PM-4:00PM: Abstract Number: 1788

Anti-neutrophil Extracellular Trap (NET) Autoantibodies in Primary Antiphospholipid Syndrome

4M087: Antiphospholipid Syndrome (1788–1793)

2:30PM-4:00PM: Abstract Number: 1791

Antiphospholipid Antibody Profile Stability over Time: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

4M087: Antiphospholipid Syndrome (1788–1793)

2:30PM-4:00PM: Abstract Number: 1817

Arthropathy of Down Syndrome: An Under-diagnosed Inflammatory Joint Disease That Warrants a Name Change

4M092: Pediatric Rheumatology – Clinical II: JIA (1812–1817)

2:30PM-4:00PM: Abstract Number: 1828

Avascular Necrosis Is Associated with APOL1 Variants in African Americans with Systemic Lupus Erythematosus

3S082: SLE – Clinical II: Flares & Morbidity of SLE (1824–1829)

2:30PM-4:00PM: Abstract Number: 1767

Biomarker Profiling Reveals Novel Mechanistic Insights into Ustekinumab Therapeutic Responses in Systemic Lupus Erythematosus

4M088: Cytokines & Cell Trafficking (1764–1769)

2:30PM-4:00PM: Abstract Number: 1776

Causal Effect of TNF-α, IL-12p70, IL-17 Levels on the Risk of Psoriatic Arthritis: A Mendelian Randomization Study

4M095: Spondyloarthritis Including Psoriatic Arthritis – Basic Science (1776–1781)

2:30PM-4:00PM: Abstract Number: 1764

CCL25, a Novel Fibroblast and Macrophage Chemoattractant That Potentiates RA Bone Erosion

4M088: Cytokines & Cell Trafficking (1764–1769)

2:30PM-4:00PM: Abstract Number: 1775

Cholesterol Sequestering in Macrophages Contributes to the Lipid Paradox in Chronic Arthritis

4M093: RA – Animal Models (1770–1775)

2:30PM-4:00PM: Abstract Number: 1772

Chronotherapy Using Baricitinib Attenuates Collagen-induced Arthritis in Mice

4M093: RA – Animal Models (1770–1775)

2:30PM-4:00PM: Abstract Number: 1779

CLEC5A/MDL-1 Is Critical for Inflammatory Arthritis and Skin Inflammation

4M095: Spondyloarthritis Including Psoriatic Arthritis – Basic Science (1776–1781)

2:30PM-4:00PM: Abstract Number: 1827

Clinical Implications of Neutrophil Extracellular Traps in Systemic Lupus Erythematosus

3S082: SLE – Clinical II: Flares & Morbidity of SLE (1824–1829)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].